Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for NMB reversal in the ICU
NCT03791801Unknown
- Sponsor
- McGill University Health Centre
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in neuromuscular blockade (NMB), sponsored by McGill University Health Centre. Primary endpoints: Time to Train of Four ratio >0.9 up to 12 weeks and Time to return of Train of Four count of 1 up to 12 weeks. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03791801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791801.